🫀 Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy)
UseUse to set the core regimen: HFrEF (LVEF ≤ 40%) starts all four pillars early, HFmrEF prefers an SGLT2i, and …
SourceChinese Society of Cardiology. Guideline for the diagnosis and treatment of heart failure in China …
This-shift next steps
After scoring: open the scene pack, peer scores, and the matching pathway. Local reference — no HIS write.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
Methodology · worked example, guidelines & full notes
Switching to ARNI requires stopping an ACEi beforehand (washout per labeling) to avoid angioedema, and the four pillars are combined early rather than sequentially. (original synthesis · not guideline verbatim)
When to use
Use to set the core regimen: HFrEF (LVEF ≤ 40%) starts all four pillars early, HFmrEF prefers an SGLT2i, and HFpEF centers on SGLT2i plus diuresis and comorbidity management.
How it works
LVEF ≤ 40% → ARNI + β-blocker + MRA + SGLT2i titrated to target; 41–49% → SGLT2i preferred; ≥ 50% → SGLT2i + diuresis + comorbidities. Flags low SBP, high K and low eGFR.
Key points
- Switching to ARNI requires stopping an ACEi beforehand (washout per labeling) to avoid angioedema, and the four pillars are combined early rather than sequentially. (original synthesis · not guideline verbatim)
- MRA/RASi require potassium and renal-function monitoring; MRA is generally avoided at markedly reduced eGFR.
- If LVEF stays ≤ 35% with symptoms after optimized therapy, evaluate for ICD/CRT.
References
- [Guideline / primary source]Chinese Society of Cardiology. Guideline for the diagnosis and treatment of heart failure in China 2024.
- [Guideline / primary source]Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation 2022.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Left ventricular ejection fraction LVEF | 32 % |
|---|---|
| Systolic BP (optional) | 110 mmHg |
| eGFR (optional) | 60 mL/min/1.73m² |
| Potassium (optional) | 4.2 mmol/L |
→Treatment directionNew quadruple therapy: ARNI + β-blocker + MRA + SGLT2i
- HF classification：HFrEF (LVEF ≤ 40%)
- Core regimen：Start the 'new quadruple therapy' early in combination and titrate to target/maximum tolerated: (1) ARNI (sacubitril/valsartan, preferred over ACEi/ARB; ACEi if not usable, ARB if ACEi not tolerated); (2) evidence-based β-blocker (bisoprolol/carvedilol/metoprolol succinate); (3) MRA (spironolactone/eplerenone); (4) SGLT2i (dapagliflozin/empagliflozin, regardless of diabetes). Add a loop diuretic symptomatically for congestion.
- Drug cautions：Switching to ARNI requires stopping ACEi; monitor BP, potassium, and renal function during initiation and titration
Verification & sources · governance
FAQ
Frequently asked questions
- What are the limits and cautions when using Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy)?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- Does Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy) upload patient data? Where is it calculated?
- Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.
- How is Guideline-Directed Medical Therapy for Heart Failure (HFrEF new quadruple therapy) calculated in practice? Can you show a worked example?
- Inputs: Left ventricular ejection fraction LVEF 32 %, Systolic BP (optional) 110 mmHg, eGFR (optional) 60 mL/min/1.73m², Potassium (optional) 4.2 mmol/L → Result: Treatment direction New quadruple therapy: ARNI + β-blocker + MRA + SGLT2i（HF classification: HFrEF (LVEF ≤ 40%), Core regimen: Start the 'new quadruple therapy' early in combination and titrate to target/maximum tolerated: (1) ARNI (sacubitril/valsartan, preferred over ACEi/ARB; ACEi if not usable, ARB if ACEi not tolerated); (2) evidence-based β-blocker (bisoprolol/carvedilol/metoprolol succinate); (3) MRA (spironolactone/eplerenone); (4) SGLT2i (dapagliflozin/empagliflozin, regardless of diabetes). Add a loop diuretic symptomatically for congestion., Drug cautions: Switching to ARNI requires stopping ACEi; monitor BP, potassium, and renal function during initiation and titration）